Jupiter Neurosciences to Participate in NobleCon21

Rhea-AI Summary

Jupiter Neurosciences (NASDAQ: JUNS) announced that its management team will present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (NobleCon21) on December 2–3, 2025 in Boca Raton, Florida.

Management will be available for qualified one-on-one investor meetings during the event and investors can schedule meetings by contacting a NobleCon representative or investor relations via JUNS@redchip.com. NobleCon21 is described as a forum for emerging growth companies, investor access, presentations, and networking opportunities.

News Market Reaction

-1.67%

2 alerts

-1.67% News Effect

-$690K Valuation Impact

$41M Market Cap

0.0x Rel. Volume

On the day this news was published, JUNS declined 1.67%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $690K from the company's valuation, bringing the market cap to $41M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: December 2–3, 2025 Conference edition: 21st Annual

2 metrics

Conference dates December 2–3, 2025 NobleCon21 Emerging Growth Equity Conference

Conference edition 21st Annual Noble Capital Markets’ NobleCon21 conference

Market Reality Check

Price: $0.8900 Vol: Volume 105,419 is 2.58x t...

high vol

$0.8900 Last Close

Volume Volume 105,419 is 2.58x the 20-day average, indicating elevated trading interest ahead of the conference. high

Technical Shares are trading below the 200-day MA of 1.15, reflecting a weak longer-term trend.

Peers on Argus

Among close biotech peers, several traded lower today (e.g., one peer down 5–6%)...

1 Down

Among close biotech peers, several traded lower today (e.g., one peer down 5–6%), while another gained over 12%, indicating mixed sector action rather than a unified move tied to this conference update.

Historical Context

5 past events · Latest: Dec 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 03	Corporate milestone recap	Positive	+2.5%	First-year public company review highlighting clinical, commercial, and financing progress.
Dec 02	Conference participation	Neutral	-1.7%	Announcement of management presentation and 1x1 meetings at NobleCon21 conference.
Nov 05	IND clearance	Positive	+8.8%	FDA clearance of IND to initiate Phase 2a JOTROL trial in Parkinson’s disease.
Oct 27	Financing agreements	Positive	+11.1%	Yorkville financing agreements providing up to $20M via notes and equity line.
Sep 15	Brand ambassador	Positive	+5.3%	Appointment of new Nugevia brand ambassador to support longevity supplement line.

Pattern Detected

Recent company news, especially clinical and financing milestones, has often coincided with positive price reactions.

Recent Company History

Over the last six months, Jupiter Neurosciences reported multiple milestones around JOTROL™ and its Nugevia™ brand. An FDA IND clearance for a Phase 2a Parkinson’s trial on Nov 5, 2025 and Yorkville financing agreements for up to $20 million both saw positive price reactions. Brand-building for Nugevia, including a new ambassador and a first-year public company recap, also aligned with gains. Today’s NobleCon21 participation fits into this pattern of visibility and investor outreach rather than a discrete clinical or financing catalyst.

Market Pulse Summary

This announcement highlights Jupiter Neurosciences’ participation at NobleCon21 on December 2–3, 202...

Analysis

This announcement highlights Jupiter Neurosciences’ participation at NobleCon21 on December 2–3, 2025, emphasizing investor outreach through presentations and one-on-one meetings. In recent months, the company reported an FDA-cleared IND for a Phase 2a Parkinson’s trial and financing arrangements for up to $20 million, alongside Nugevia™ brand-building. Investors may track how conference exposure complements these clinical and financing milestones and monitor upcoming trial enrollment and corporate updates.

Key Terms

clinical-stage, resveratrol-based, neuroinflammation, mitochondrial dysfunction

4 terms

clinical-stage medical

"a clinical-stage pharmaceutical company developing JOTROL™..."

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

resveratrol-based medical

"a patented resveratrol-based therapeutic platform targeting..."

Products, treatments, or formulations that use resveratrol—a naturally occurring compound found in certain plants—as a primary active ingredient or key selling feature. For investors, “resveratrol-based” signals a focus on antioxidant, anti-inflammatory, or longevity claims that can affect market demand, regulatory review, and clinical evidence requirements; think of it as a product built around a single headline ingredient, like a car marketed mainly for its electric motor. The term does not guarantee effectiveness or regulatory approval.

neuroinflammation medical

"therapeutic platform targeting neuroinflammation and mitochondrial dysfunction"

Neuroinflammation is the brain or spinal cord’s immune reaction to injury, infection, or abnormalities, where cells and molecules become active to protect or repair nervous tissue. It matters to investors because it underlies many neurological diseases and is a common target for drugs and diagnostic tools; positive or negative trial results, safety signals, or new therapies can change a company’s value much like a major repair plan or recall would affect a carmaker’s prospects.

mitochondrial dysfunction medical

"therapeutic platform targeting neuroinflammation and mitochondrial dysfunction"

Mitochondrial dysfunction is when the cell’s energy factories, called mitochondria, fail to make enough energy for cells to work properly, which can cause tissue damage and contribute to many diseases. For investors, it matters because therapies, tests, or devices aimed at fixing or detecting this problem can create market opportunities or clinical risk; think of it as a failing car battery that drives demand for repairs, replacements, and related medical products.

AI-generated analysis. Not financial advice.

Jupiter, Florida--(Newsfile Corp. - December 2, 2025) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL^™, a patented resveratrol-based therapeutic platform targeting neuroinflammation and mitochondrial dysfunction, today announced that its management team will present at the upcoming Noble Capital Markets' 21^st Annual Emerging Growth Equity Conference on December 2-3, 2025, in Boca Raton, FL.

Held annually in South Florida, NobleCon brings together public company executives, institutional investors, family offices, and industry leaders for a high-impact, in-person experience.

Management will be available during the event for one-on-one meetings with the investment community. To schedule a meeting, please contact your NobleCon representative or Jupiter Neurosciences' investor relations by emailing JUNS@redchip.com.

NobleCon21 is the premier forum for emerging growth companies, investor access, and networking, designed to maximize visibility and engagement for small and mid-cap companies through presentations, qualified one-on-one investor meetings and receptions.

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be found on the Company's website www.jupiterneurosciences.com.

About JOTROL

Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.

Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL^™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer's Disease trial, and Yui et al., Friedreich's Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL^™ trials, were published in the Journal of Alzheimer's Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL^™ toward a Phase IIa trial in Parkinson's Disease.

In addition to its therapeutic applications, JOTROL^™ serves as the foundation for Jupiter's Nugevia consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy.

FORWARD-LOOKING STATEMENTS

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations, including the Company's ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company's final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.

Contact:
IR@jupiterneurosciences.com
JUNS@redchip.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276669

FAQ

When will Jupiter Neurosciences (JUNS) present at NobleCon21?

Jupiter Neurosciences management will present on December 2–3, 2025 at NobleCon21 in Boca Raton, FL.

How can investors schedule a one-on-one meeting with JUNS management at NobleCon21?

Investors can schedule meetings by contacting their NobleCon representative or emailing investor relations at JUNS@redchip.com.

What topics will JUNS management cover at the NobleCon21 presentation?

The announcement states management will present recent developments and be available for investor meetings; no specific presentation topics or slides were disclosed.

Where is NobleCon21 being held for Jupiter Neurosciences' presentation?

NobleCon21 is being held in Boca Raton, Florida on December 2–3, 2025.

Is there a webcast or public replay of Jupiter Neurosciences' NobleCon21 presentation?

The announcement does not specify a webcast or replay availability; contact investor relations at JUNS@redchip.com for access details.

What is the purpose of JUNS attending NobleCon21 for investors?

Attendance provides investor access for one-on-one meetings, presentations, and networking with emerging growth company executives and institutional investors.